Atika Capital Management LLC Mirati Therapeutics, Inc. Transaction History

Atika Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$144.0 - $179.73 $4.9 Million - $6.11 Million	-34,000 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$158.92 - $221.61 $2.15 Million - $2.99 Million	-13,500 Reduced 28.42%	34,000 $5.82 Million
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $3.97 Million - $5.89 Million	24,500 Added 106.52%	47,500 $10.4 Million
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $1.87 Million - $2.63 Million	-24,000 Reduced 51.06%	23,000 $1.79 Million
Q2 2019 Aug 12, 2019	BUY	$59.49 - $104.71 $2.8 Million - $4.92 Million	47,000 New	47,000 $4.84 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Atika Capital Management LLC with notifications on news.